For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Celldex Therapeutics Inc’s stock clocked out at $27.09, down -1.53% from its previous closing price of $27.51. In other words, the price has decreased by -$1.53 from its previous closing price. On the day, 0.86 million shares were traded. CLDX stock price reached its highest trading level at $27.9 during the session, while it also had its lowest trading level at $26.8193.
Ratios:
To gain a deeper understanding of CLDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.01 and its Current Ratio is at 13.01. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Mizuho on October 21, 2025, initiated with a Outperform rating and assigned the stock a target price of $48.
On October 13, 2025, Barclays started tracking the stock assigning a Underweight rating and target price of $25.
On April 28, 2025, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $64.Canaccord Genuity initiated its Buy rating on April 28, 2025, with a $64 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 04 ’25 when Jimenez Freddy A. sold 4,166 shares for $29.09 per share. The transaction valued at 121,210 led to the insider holds 30,796 shares of the business.
FREDDY A JIMENEZ bought 4,166 shares of CLDX for $121,210 on Dec 04 ’25. On Nov 13 ’25, another insider, Wright Richard M., who serves as the Former Officer of the company, sold 49,298 shares for $24.00 each. As a result, the insider received 1,183,177 and left with 20,833 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 1800116224 and an Enterprise Value of 1219514112. For the stock, the TTM Price-to-Sale (P/S) ratio is 692.35 while its Price-to-Book (P/B) ratio in mrq is 3.01. Its current Enterprise Value per Revenue stands at 469.224 whereas that against EBITDA is -4.823.
Stock Price History:
The Beta on a monthly basis for CLDX is 1.19, which has changed by 0.05645156 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, CLDX has reached a high of $30.50, while it has fallen to a 52-week low of $14.40. The 50-Day Moving Average of the stock is 2.76%, while the 200-Day Moving Average is calculated to be 20.19%.
Shares Statistics:
It appears that CLDX traded 919.85K shares on average per day over the past three months and 878880 shares per day over the past ten days. A total of 66.45M shares are outstanding, with a floating share count of 64.57M. Insiders hold about 2.82% of the company’s shares, while institutions hold 107.36% stake in the company. Shares short for CLDX as of 1764288000 were 8675509 with a Short Ratio of 9.43, compared to 1761868800 on 7509487. Therefore, it implies a Short% of Shares Outstanding of 8675509 and a Short% of Float of 15.42.
Earnings Estimates
The performance of Celldex Therapeutics Inc (CLDX) in the stock market is under the watchful eye of 12.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$1.05, with high estimates of -$0.96 and low estimates of -$1.2.
Analysts are recommending an EPS of between -$3.24 and -$3.68 for the fiscal current year, implying an average EPS of -$3.58. EPS for the following year is -$4.41, with 10.0 analysts recommending between -$4.01 and -$4.87.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for CLDX’s current fiscal year. The highest revenue estimate was $7M, while the lowest revenue estimate was $1.4M, resulting in an average revenue estimate of $2.79M. In the same quarter a year ago, actual revenue was $7.02M
